With that in mind, let's consider two stocks down 17% and 36%, respectively, this year that are worth investing in right now: ...

The FDA has approved the popular drug Dupixent (generic name, dupilumab) for adults and kids 12 and up with chronic spontaneous urticaria (CSU), a long-lasting itchy skin condition, when regular ...

The FDA had rejected the companies’ initial application in 2023, requesting additional data after the pharma firms reported ...

The company reiterated its financial outlook for the year but is struggling to predict the likely impact of pharmaceutical ...

Sanofi Q1 2025 revenue rose 10.8% to $10.42 billion, driven by Dupixent and new launches, as earnings climbed 20.1% and 2025 guidance was reaffirmed.

Galderma has kicked off an ad campaign to show how its Nemluvio can empower people to rule over itchy eczema. Aiming to grow ...

GLP-1s exploded seemingly out of nowhere, straining pharmacy plan bottom lines. Psoriasis treatments don't have to follow the ...

Roche beat first-quarter sales expectations Thursday, while Sanofi's sales report came in mixed. Shares were muted in ...

Dupixent, an interleukin-4 and 13 inhibitor, was approved in Europe in asthma in May last year, following a previous approval in eczema. The type 2 inflammation that this label covers occurs in ...